GENE THERAPY AND GENE-MODIFIED CELL THERAPY IN RARE DISEASES



Gene therapy and gene-modified cell therapies offer the potential to help patients with rare diseases to cure or improve their disease



Leber congenital amaurosis



Spinal muscular atrophy



Reta -Thalassemia



Adrenoleukodystrophy



Hemophilia A and B

There are many other rare diseases that gene therapy is currently being developed for

Patient Education

Patients should be informed and educated on gene therapy

2. Shared-Decision Making and Informed Consent

Implementation of gene therapy requires a multidisciplinary approach with the patient being central



3. Follow-up

Patients should be included in a registry to ensure long-term follow-up

FURTHER READING



Gene Therapy Basics (2022 Update)

Gene Therapy: The Basics - FAQs²



Landscape Report³

<u>American Society of Gene + Cell therapy</u>

Educational Resources Directory⁴

European Consortium for Communicating Gene & Cell Therapy Information

E-learnings gene therapy and hemophilia⁵ World Federation of Hemophilia



Papaioannou, et al.6

Clinical applications of gene therapy for rare diseases: A review

2023

Samelson-Jones, et al.7

Adeno-Associated Virus Gene Therapy for Hemophilia

2023

Hermans, et al.8

How to translate and implement the current science of gene

2023 therapy into haemophilia care?

Gene therapy is expected to become a major treatment approach for many rare diseases in the future

1. Gene Therapy Basics (2022 Update), American Society of Gene + Cell Therapy, ASGCT, https://www.youtube.com/watch?v=kAtd9X29SdQ; 2. Gene Therapy: The Basics - FAQs, National Bleeding Disorders Foundation, https://youtu.be/USUYAKkCrB0?si=6tidK25jOr6ZaAiy; 3. Gene, Cell, & RNA Therapy Landscape Report, American Society of Gene + Cell Therapy, ASGCT, https://asgct.org/publications/landscape-report; 4. Educational Resources Directory, EuroGCT, https://www.eurogct.org/discover-gene-and-cell-therapy/educational-resources-directory; 5. eLearning WFH educational platform, World Federation of Hemophilia, https://elearning.wfh.org/resource/gene-therapy-for-hemophilia-what-why-how-when-who-and-where/;

6. Papaioannou I, et al. Int J Exp Pathol. 2023;104:154-176; 7. Samelson-Jones BJ and George LA. Annu Rev Med. 2023;74:231-247; 8. Hermans C, et al. Ther Adv Hematol. 2023;14:20406207221145627

This programme was developed by international experts Prof. Cedric Hermans (Saint-Luc University, Belgium) and Prof. Miguel Escobar (Houston McGovern Medical School and University of Texas M.D. Anderson Cancer Center, USA) and is an initiative of COR2ED. The programme is supported by an independent educational grant from the American Society of Gene + Cell Therapy (ASGCT) and Pfizer. The programme is therefore independent; the content is not influenced by the supporter and is under the sole responsibility of the experts. The views expressed are the personal opinions of the experts. They do not necessarily represent the views of the experts' institutions.

Go to COR2ED.COM for more information and resources

